According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab ... with expected sales of $10 billion. The breast cancer drug Ibrance (palbociclib), ranked eighth, has emerged as a big earner ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...